57005-71-7

Basic information

• Product Name: 2-(4-METHYL-1-PIPERAZINYL)-4-PYRIMIDINAMINE
• Synonyms: 2-(4-METHYL-1-PIPERAZINYL)-4-PYRIMIDINAMINE;2-(4-Methylpiperazin-1-yl)pyriMidin-4-aMine;2-(4-Methyl-piperazin-1-yl)-pyrimidin-4-ylamine
• CAS NO: 57005-71-7
• Molecular Formula: C₉H₁₅N₅
• Molecular Weight: 193.25
• Mol File: 57005-71-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 386.3°C at 760 mmHg
• Flash Point: 187.4°C
• Appearance: /
• Density: 1.196g/cm³
• Vapor Pressure: 3.57E-06mmHg at 25°C
• Refractive Index: 1.598
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 2-(4-METHYL-1-PIPERAZINYL)-4-PYRIMIDINAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-METHYL-1-PIPERAZINYL)-4-PYRIMIDINAMINE(57005-71-7)
• EPA Substance Registry System: 2-(4-METHYL-1-PIPERAZINYL)-4-PYRIMIDINAMINE(57005-71-7)

Safety Data

• Hazardous Substances Data: 57005-71-7(Hazardous Substances Data)

Usage

General Description

2-(4-Methyl-1-piperazinyl)-4-pyrimidinamine is a chemical compound that belongs to the class of piperazine derivatives. It is commonly used as an intermediate in the synthesis of pharmaceutical compounds. 2-(4-METHYL-1-PIPERAZINYL)-4-PYRIMIDINAMINE has shown potential therapeutic applications in the treatment of various diseases, including cancer, and has been studied for its anti-tumor and anti-viral properties. It is also utilized in the development of drugs targeting central nervous system disorders. The chemical structure of 2-(4-Methyl-1-piperazinyl)-4-pyrimidinamine makes it a versatile building block for the synthesis of diverse bioactive molecules with potential pharmacological activities.

InChI:InChI=1/C9H15N5/c1-13-4-6-14(7-5-13)9-11-3-2-8(10)12-9/h2-3H,4-7H2,1H3,(H2,10,11,12)

Upstream product

• 109-01-3 1-methyl-piperazine 
• 7461-50-9 2-chloropyrimidin-4-amine 

Relevant articles and documents

Optimization of Physicochemical Properties for 4-Anilinoquinoline Inhibitors of Plasmodium falciparum Proliferation

We recently reported the medicinal chemistry reoptimization of a known human tyrosine kinase inhibitor, lapatinib, against a variety of parasites responsible for numerous tropical diseases, including human African trypanosomiasis (Trypanosoma brucei), Chagas disease (T. cruzi), Leishmaniasis (Leishmania spp.), and malaria (Plasmodium falciparum). Herein, we report our continuing efforts to optimize this series against P. falciparum. Through the design of a library of compounds focused on reducing the lipophilicity and molecular weight, followed by an SAR exploration, we have identified NEU-1953 (40). This compound is a potent inhibitor of P. falciparum with an improved ADME profile over the previously reported compound, NEU-961 (3).

Peptide deformylase inhibitors

The present invention relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods directed to bacterial infections and inhibition of bacterial peptide deformylase (PDF) activity.

CYTOKINE INHIBITORS

The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are useful as anti-inflammatory agents. There are further provided methods for the preparation of such agents and their use in preventing or treating conditions mediated by cytokines, such as for example arthritis, pain, cardiovascular disease and cancer.